知镜 Cognispect · 医学文献与研究工作台

A Large Multicenter Cohort of Ataxia-Telangiectasia: Clinical, Immunologic, Genetic, and Survival Outcomes.

Fekrvand S, Firouzabadi A, Vakilipour P, Safari D, Delavari S, Mehrabadi AZ, Chavoshzadeh Z, Esmaeilzadeh H, Sharafian S, DorriMoghaddam F, Sadeghi-Shabestari M, Monfared FT, Afkham EK, Aleyasin S, Abolnezhadian F, Salyanchi R, Ahanchian H, Kalantari A, Behniafard N, Momen T, Sherkat R, Tavakol M, Barzamini S, Shafiei A, Cheraghi T, Vosughimotlagh A, Sepahi N, Olbrich P, Meyts I, Gennery AR, Abolhassani H, Rezaei N, Yazdani R.
European journal of neurology · 2026-11-01 · PMID 42969471

文献摘要

Background Ataxia telangiectasia (AT) is a life-threatening multisystem disorder characterized mainly by neurologic manifestations, infections, and malignancy. We aimed to present a comprehensive analysis of demographic, clinical, immunologic, and genetic features and outcomes of patients with AT in Iran. Methods We conducted a retrospective cohort study of 305 registered patients with AT enrolled through a national referral network (2002-2025). Diagnosis was established according to the European Society for Immunodeficiencies criteria. Results Mean age at diagnosis and mean age at onset were 72.0 (±46.0) and 25.2 (±35.57) months, respectively. A substantial proportion of patients presented with non-neurological manifestations as their first clinical feature (43.9%). Among non-neurological manifestations, pneumonia was the second most common initial manifestation (13%) and the most frequent infectious complication (30.2%). Variants classified as severe under the predicted loss-of-function (PVS1) criteria were identified in 104 patients, representing 83.8% of those who underwent genetic evaluation. Immunoglobulin abnormalities were detected in 84.7% of patients. A notable proportion of patients showed class switching recombination defects (45.6%), which were associated with a higher burden of clinical morbidity. Median age at death was 12.8 years (95% CI, 11.0-15.0), and the estimated overall survival rates at 5 and 10 years were 81.6% and 60.2%, respectively. Malignancy (28.9%) and respiratory tract infections (20.0%) were the most common causes of death, respectively. Conclusion This large national cohort provides a comprehensive characterization of the clinical, immunologic, and genetic landscape of AT and its determinants of outcome, thereby improving diagnostic recognition, risk stratification, and patient management.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。